Phreesia, Inc. (NYSE:PHR – Get Free Report) CEO Chaim Indig sold 6,555 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $20.34, for a total value of $133,328.70. Following the completion of the sale, the chief executive officer now directly owns 1,245,291 shares of the company’s stock, valued at approximately $25,329,218.94. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Phreesia Stock Performance
PHR stock opened at $20.08 on Friday. Phreesia, Inc. has a twelve month low of $20.07 and a twelve month high of $40.00. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average of $28.81 and a 200 day moving average of $30.91.
Phreesia (NYSE:PHR – Get Free Report) last posted its earnings results on Wednesday, September 6th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. The business had revenue of $85.80 million during the quarter, compared to analyst estimates of $85.26 million. Phreesia had a negative return on equity of 54.52% and a negative net margin of 47.75%. The company’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.89) EPS. Analysts predict that Phreesia, Inc. will post -2.68 EPS for the current fiscal year.
Hedge Funds Weigh In On Phreesia
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the company. KeyCorp cut their price objective on Phreesia from $45.00 to $40.00 in a report on Thursday, May 25th. Piper Sandler lowered their price objective on Phreesia from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday. Raymond James decreased their price target on Phreesia from $40.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Phreesia in a research note on Thursday, September 7th. Finally, Robert W. Baird reduced their price objective on Phreesia from $40.00 to $39.00 in a research note on Thursday, September 7th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.15.
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
- Five stocks we like better than Phreesia
- 3 REITs to Buy and Hold for the Long Term
- 3 Reasons Why AMD Might Breakout Higher
- Are Penny Stocks a Good Fit for Your Portfolio?
- Build a Solid Gold Retirement With AI Powerhouse Adobe
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- 2 Wrecked Stocks Keeping Cars on the Road Ready for Repair
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.